​

2seventy bio Stock (NASDAQ:TSVT)

ForecastRevenueOwnershipFinancialsChartTranscripts
2seventy bio by TradingView

Previous Close

$5.00

52W Range

$2.29 - $5.30

50D Avg

$4.97

200D Avg

$4.05

Market Cap

$266.14M

Avg Vol (3M)

$1.46M

Beta

1.05

Div Yield

-

TSVT Company Profile

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Nov 03, 2021

Website

TSVT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Collaboration Arrangement$4.70M$19.58M-
Royalty And Other Revenue-$4.64M-
Service-$24.14M$55.49M

Fiscal year ends in Dec 24 | Currency in USD

TSVT Financial Summary

Dec 24Dec 23Dec 22
Revenue$37.86M$100.39M$91.50M
Operating Income$-115.43M$-237.61M$-262.91M
Net Income$-57.25M$-217.57M$-254.14M
EBITDA$-115.43M$-206.42M$-251.38M
Basic EPS$-1.10$-4.42$-7.13
Diluted EPS$-1.10$-4.42$-7.13

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 12, 24 | 8:00 AM
Q2 24Aug 11, 24 | 8:00 AM
Q1 24May 08, 24 | 8:00 AM

Peer Comparison

TickerCompany
CRGXCARGO Therapeutics, Inc. Common Stock
CELUCelularity Inc.
LFCRLifecore Biomedical, Inc.
SLRNAcelyrin, Inc.
TCRTAlaunos Therapeutics, Inc.
INZYInozyme Pharma, Inc.
THRDThird Harmonic Bio, Inc.